rotavirus

ロタウイルス

　

WordNet

1. the reovirus causing infant enteritis

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/03/18 10:39:52」(JST)

wiki en

[Wiki en表示]

Rotavirus
Computer–aided reconstruction of a rotavirus based on several electron micrographs
Virus classification
Group:	Group III (dsRNA)
Order:	Unassigned
Family:	Reoviridae
Subfamily:	Sedoreovirinae
Genus:	Rotavirus
Type species
Rotavirus A
Species
Rotavirus A Rotavirus B Rotavirus C Rotavirus D Rotavirus E Rotavirus F Rotavirus G Rotavirus H

Rotavirus is the most common cause of severe vomiting and diarrhoea among infants and young children. It is a genus of double-stranded RNA virus in the family Reoviridae. Nearly every child in the world has been infected with rotavirus at least once by the age of five. Immunity develops with each infection, so subsequent infections are less severe; adults are rarely affected. There are eight species of this virus, referred to as A, B, C, D, E, F, G and H. Rotavirus A, the most common species, causes more than 90% of rotavirus infections in humans.

The virus is transmitted by the fæcal-oral route. It infects and damages the cells that line the small intestine and causes gastroenteritis (which is often called "stomach flu" despite having no relation to influenza). Although rotavirus was discovered in 1973 by Ruth Bishop and her colleagues by electron micrograph images and accounts for up to 50% of hospitalisations for severe diarrhoea in infants and children, its importance has been underestimated within the public health community, particularly in developing countries. In addition to its impact on human health, rotavirus also infects animals, and is a pathogen of livestock.

Rotavirus is usually an easily managed disease of childhood, but worldwide more than 450,000 children under five years of age still die from rotavirus infection each year, most of whom live in developing countries, and almost two million more become severely ill. In the United States, before initiation of the rotavirus vaccination programme, rotavirus caused about 2.7 million cases of severe gastroenteritis in children, almost 60,000 hospitalizations, and around 37 deaths each year. Public health campaigns to combat rotavirus focus on providing oral rehydration therapy for infected children and vaccination to prevent the disease. The incidence and severity of rotavirus infections has declined significantly in countries that have added rotavirus vaccine to their routine childhood immunisation policies.

Signs and symptoms

Rotavirus gastroenteritis is a mild to severe disease characterised by nausea, vomiting, watery diarrhoea, and low-grade fever. Once a child is infected by the virus, there is an incubation period of about two days before symptoms appear. The period of illness is acute. Symptoms often start with vomiting followed by four to eight days of profuse diarrhoea. Dehydration is more common in rotavirus infection than in most of those caused by bacterial pathogens, and is the most common cause of death related to rotavirus infection. Symptoms of dehydration associated with Rotavirus include dizziness while standing, decrease in urination and dry mouth and throat.

Rotavirus A infections can occur throughout life: the first usually produces symptoms, but subsequent infections are typically mild or asymptomatic, as the immune system provides some protection. Consequently, symptomatic infection rates are highest in children under two years of age and decrease progressively towards 45 years of age. Infection in newborn children, although common, is often associated with mild or asymptomatic disease; the most severe symptoms tend to occur in children six months to two years of age, the elderly, and those with compromised or absent immune system functions. Due to immunity acquired in childhood, most adults are not susceptible to rotavirus; gastroenteritis in adults usually has a cause other than rotavirus, but asymptomatic infections in adults may maintain the transmission of infection in the community.

Transmission

Rotaviruses in the faeces of an infected child

Rotavirus is transmitted by the fæcal-oral route, via contact with contaminated hands, surfaces and objects, and possibly by the respiratory route. Viral diarrhea is highly contagious. The faeces of an infected person can contain more than 10 trillion infectious particles per gram; fewer than 100 of these are required to transmit infection to another person.

Rotaviruses are stable in the environment and have been found in estuary samples at levels up to 1–5 infectious particles per US gallon, the viruses survive between 9 and 19 days. Sanitary measures adequate for eliminating bacteria and parasites seem to be ineffective in control of rotavirus, as the incidence of rotavirus infection in countries with high and low health standards is similar.

Disease mechanisms

Electron micrograph of a rotavirus infected enterocyte (top) compared to an uninfected cell (bottom). The bar = approx. 500 nm

The diarrhoea is caused by multiple activities of the virus. Malabsorption occurs because of the destruction of gut cells called enterocytes. The toxic rotavirus protein NSP4 induces age- and calcium ion-dependent chloride secretion, disrupts SGLT1 transporter-mediated reabsorption of water, apparently reduces activity of brush-border membrane disaccharidases, and possibly activates the calcium ion-dependent secretory reflexes of the enteric nervous system. Healthy enterocytes secrete lactase into the small intestine; milk intolerance due to lactase deficiency is a symptom of rotavirus infection, which can persist for weeks. A recurrence of mild diarrhoea often follows the reintroduction of milk into the child's diet, due to bacterial fermentation of the disaccharide lactose in the gut.

Diagnosis and detection

Diagnosis of infection with rotavirus normally follows diagnosis of gastroenteritis as the cause of severe diarrhoea. Most children admitted to hospital with gastroenteritis are tested for rotavirus A. Specific diagnosis of infection with rotavirus A is made by finding the virus in the child's stool by enzyme immunoassay. There are several licensed test kits on the market which are sensitive, specific and detect all serotypes of rotavirus A. Other methods, such as electron microscopy and PCR, are used in research laboratories. Reverse transcription-polymerase chain reaction (RT-PCR) can detect and identify all species and serotypes of human rotavirus.

Treatment and prognosis

Treatment of acute rotavirus infection is nonspecific and involves management of symptoms and, most importantly, maintenance of hydration. If untreated, children can die from the resulting severe dehydration. Depending on the severity of diarrhoea, treatment consists of oral rehydration, during which the child is given extra water to drink that contains small amounts of salt and sugar. In 2004, the WHO and UNICEF recommended the use of low-osmolarity oral rehydration solution and zinc supplementation as a two-pronged treatment of acute diarrhoea. Some infections are serious enough to warrant hospitalization where fluids are given by intravenous drip or nasogastric tube, and the child's electrolytes and blood sugar are monitored. Probiotics have been shown to reduce the duration of rotavirus diarrhoea, and according to the European Society for Pediatric Gastroenterology "effective interventions include administration of specific probiotics such as Lactobacillus GG or Saccharomyces boulardii, diosmectite or racecadotril." Rotavirus infections rarely cause other complications and for a well managed child the prognosis is excellent.

Epidemiology

The seasonal variation of rotavirus A infections in a region of England: rates of infection peak during the winter months.

Rotavirus A, which accounts for more than 90% of rotavirus gastroenteritis in humans, is endemic worldwide. Each year rotavirus causes millions of cases of diarrhoea in developing countries, almost 2 million resulting in hospitalization and an estimated 453,000 resulting in the death of a child younger than five, 85 percent of whom live in developing countries. In the United States alone—before initiation of the rotavirus vaccination programme—over 2.7 million cases of rotavirus gastroenteritis occurred annually, 60,000 children were hospitalised and around 37 died from the results of the infection. The major role of rotavirus in causing diarrhoea is not widely recognised within the public health community, particularly in developing countries. Almost every child has been infected with rotavirus by age five. It is the leading single cause of severe diarrhoea among infants and children, being responsible for about 20% of cases, and accounts for 50% of the cases requiring hospitalization. Rotavirus causes 37% of deaths attributable to diarrhoea and 5% of all deaths in children younger than five. Boys are twice as likely as girls to be admitted to hospital. Rotavirus infections occur primarily during cool, dry seasons. The number attributable to food contamination is unknown.

"Rotavirus is estimated to cause about 40 per cent of all hospital admissions due to diarrhoea among children under five years of age worldwide—leading to some 100 million episodes of acute diarrhoea each year that result in 350,000 to 600,000 child deaths."

UNICEF and World Health Organization

Outbreaks of rotavirus A diarrhoea are common among hospitalised infants, young children attending day care centres, and elderly people in nursing homes. An outbreak caused by contaminated municipal water occurred in Colorado in 1981. During 2005, the largest recorded epidemic of diarrhoea occurred in Nicaragua. This unusually large and severe outbreak was associated with mutations in the rotavirus A genome, possibly helping the virus escape the prevalent immunity in the population. A similar large outbreak occurred in Brazil in 1977.

Rotavirus B, also called adult diarrhoea rotavirus or ADRV, has caused major epidemics of severe diarrhoea affecting thousands of people of all ages in China. These epidemics occurred as a result of sewage contamination of drinking water. Rotavirus B infections also occurred in India in 1998; the causative strain was named CAL. Unlike ADRV, the CAL strain is endemic. To date, epidemics caused by rotavirus B have been confined to mainland China, and surveys indicate a lack of immunity to this species in the United States.

Rotavirus C has been associated with rare and sporadic cases of diarrhoea in children, and small outbreaks have occurred in families.

Prevention

Main article: Rotavirus vaccine

Because improved sanitation does not decrease the prevalence of rotaviral disease, and the rate of hospitalizations remains high despite the use of oral rehydrating medicines, the primary public health intervention is vaccination. Two vaccines against Rotavirus A infection are safe and effective in children: Rotarix by GlaxoSmithKline and RotaTeq by Merck. Both are taken orally and contain attenuated live virus. In 2009, the World Health Organization (WHO) recommended that rotavirus vaccine be included in all national immunisation programmes. The incidence and severity of rotavirus infections has declined significantly in countries that have acted on this recommendation. In Mexico, which in 2006 was among the first countries in the world to introduce rotavirus vaccine, diarrhoeal disease death rates dropped during the 2009 rotavirus season by more than 65 percent among children age two and under. In Nicaragua, which in 2006 became the first developing country to introduce a rotavirus vaccine, severe rotavirus infections were reduced by 40 percent and emergency room visits by a half. In the United States, rotavirus vaccination since 2006 has led to drops in rotavirus-related hospitalizations by as much as 86 percent. The vaccines may also have prevented illness in non-vaccinated children by limiting the number of circulating infections.

Rotavirus vaccines are licensed in more than 100 countries, but only 28 countries have introduced routine rotavirus vaccination. Following the introduction of routine rotavirus vaccination in the US in 2006, the health burden of rotavirus gastroenteritis "rapidly and dramatically reduced" despite lower coverage levels compared to other routine infant immunizations. Clinical trials of the Rotarix rotavirus vaccine in South Africa and Malawi, found that the vaccine significantly reduced severe diarrhoea episodes caused by rotavirus, and that the infection was preventable by vaccination. Safety and efficacy trials of Rotarix and RotaTeq in Africa and Asia found that the vaccines dramatically reduced severe disease among infants in developing countries, where the majority of rotavirus deaths occur. A 2012 Cochrane review of 41 clinical trials that included 186,263 participants concluded Rotarix and RotaTeq are effective vaccines. Additional rotavirus vaccines are under development. In September 2013, the vaccine will be offered to all children in the UK, aged between two and three months, and it is expected to halve the cases of severe infection and reduce the number of children admitted to hospital because of the infection by 70 percent.

International non-governmental organization PATH, the WHO, the U.S. Centers for Disease Control and Prevention, and the GAVI Alliance are working to bring rotavirus vaccines to developing countries, where children face the greatest burden. Through the Rotavirus Vaccine Program and the Accelerating Vaccine Introduction initiative, these groups are partnering with research institutions and governments to reduce child morbidity and mortality from diarrhoeal disease by making a vaccine against rotavirus available for use in developing countries.

Infections of other animals

Rotaviruses infect the young of many species of animals and they are a major cause of diarrhoea in wild and reared animals worldwide. As a pathogen of livestock, notably in young calves and piglets, rotaviruses cause economic loss to farmers because of costs of treatment associated with high morbidity and mortality rates. These rotaviruses are a potential reservoir for genetic exchange with human rotaviruses. There is evidence that animal rotaviruses can infect humans, either by direct transmission of the virus or by contributing one or several RNA segments to reassortants with human strains.

Virology

Types of rotavirus

There are eight species of rotavirus, referred to as A, B, C, D, E, F, G, and H. Humans are primarily infected by species A, B and C, most commonly by species A. A–E species cause disease in other animals. Within rotavirus A there are different strains, called serotypes. As with influenza virus, a dual classification system is used based on two proteins on the surface of the virus. The glycoprotein VP7 defines the G serotypes and the protease-sensitive protein VP4 defines P serotypes. Because the two genes that determine G-types and P-types can be passed on separately to progeny viruses, different combinations are found.

Structure

The genome of rotavirus consists of 11 unique double helix molecules of RNA which are 18,555 nucleotides in total. Each helix, or segment, is a gene, numbered 1 to 11 by decreasing size. Each gene codes for one protein, except genes 9, which codes for two. The RNA is surrounded by a three-layered icosahedral protein capsid. Viral particles are up to 76.5 nm in diameter and are not enveloped.

Proteins

There are six viral proteins (VPs) that form the virus particle (virion). These structural proteins are called VP1, VP2, VP3, VP4, VP6 and VP7. In addition to the VPs, there are six nonstructural proteins (NSPs), that are only produced in cells infected by rotavirus. These are called NSP1, NSP2, NSP3, NSP4, NSP5 and NSP6.

A simplified diagram of the location of rotavirus structural proteins

At least six of the twelve proteins encoded by the rotavirus genome bind RNA. The role of these proteins play in rotavirus replication is not entirely understood; their functions are thought to be related to RNA synthesis and packaging in the virion, mRNA transport to the site of genome replication, and mRNA translation and regulation of gene expression.

Structural proteins

VP1 is located in the core of the virus particle and is an RNA polymerase enzyme. In an infected cell this enzyme produces mRNA transcripts for the synthesis of viral proteins and produces copies of the rotavirus genome RNA segments for newly produced virus particles.

Electron micrograph of gold nanoparticles attached to rotavirus. The small dark circular objects are gold nanoparticles coated with a monoclonal antibody specific for rotavirus protein VP6.

VP2 forms the core layer of the virion and binds the RNA genome.

VP3 is part of the inner core of the virion and is an enzyme called guanylyl transferase. This is a capping enzyme that catalyses the formation of the 5' cap in the post-transcriptional modification of mRNA. The cap stabilises viral mRNA by protecting it from nucleic acid degrading enzymes called nucleases.

VP4 is on the surface of the virion that protrudes as a spike. It binds to molecules on the surface of cells called receptors and drives the entry of the virus into the cell. VP4 has to be modified by the protease enzyme trypsin, which is found in the gut, into VP5* and VP8* before the virus is infectious. VP4 determines how virulent the virus is and it determines the P-type of the virus.

VP6 forms the bulk of the capsid. It is highly antigenic and can be used to identify rotavirus species. This protein is used in laboratory tests for rotavirus A infections.

VP7 is a glycoprotein that forms the outer surface of the virion. Apart from its structural functions, it determines the G-type of the strain and, along with VP4, is involved in immunity to infection.

Nonstructural viral proteins

NSP1, the product of gene 5, is a nonstructural RNA-binding protein.

NSP2 is an RNA-binding protein that accumulates in cytoplasmic inclusions (viroplasms) and is required for genome replication.

NSP3 is bound to viral mRNAs in infected cells and it is responsible for the shutdown of cellular protein synthesis.

NSP4 is a viral enterotoxin that induces diarrhoea and was the first viral enterotoxin discovered.

NSP5 is encoded by genome segment 11 of rotavirus A. In virus-infected cells NSP5 accumulates in the viroplasm.

NSP6 is a nucleic acid binding protein and is encoded by gene 11 from an out-of-phase open reading frame.

Rotavirus genes and proteins

RNA Segment (Gene)	Size (base pairs)	Protein	Molecular weight kDa	Location	Copies per particle	Function
1	3302	VP1	125	At the vertices of the core	<25	RNA-dependent RNA polymerase
2	2690	VP2	102	Forms inner shell of the core	120	Stimulates viral RNA replicase
3	2591	VP3	88	At the vertices of the core	<25	Guanylyl transferase mRNA capping enzyme
4	2362	VP4	87	Surface spike	120	Cell attachment, virulence
5	1611	NSP1	59	Nonstructural	0	5'RNA binding
6	1356	VP6	45	Inner Capsid	780	Structural and species-specific antigen
7	1104	NSP3	37	Nonstructural	0	Enhances viral mRNA activity and shut-offs cellular protein synthesis
8	1059	NSP2	35	Nonstructural	0	NTPase involved in RNA packaging
9	1062	VP71 VP72	38 and 34	Surface	780	Structural and neutralisation antigen
10	751	NSP4	20	Nonstructural	0	Enterotoxin
11	667	NSP5 NSP6	22	Nonstructural	0	ssRNA and dsRNA binding modulator of NSP2

This table is based on the simian rotavirus strain SA11. RNA-protein coding assignments differ in some strains.

Replication

A simplified drawing of the rotavirus replication cycle

Rotaviruses replicate mainly in the gut, and infect enterocytes of the villi of the small intestine, leading to structural and functional changes of the epithelium. The triple protein coats make them resistant to the acidic pH of the stomach and the digestive enzymes in the gut.

The virus enter cells by receptor mediated endocytosis and form a vesicle known as an endosome. Proteins in the third layer (VP7 and the VP4 spike) disrupt the membrane of the endosome, creating a difference in the calcium concentration. This causes the breakdown of VP7 trimers into single protein subunits, leaving the VP2 and VP6 protein coats around the viral dsRNA, forming a double-layered particle (DLP).

The eleven dsRNA strands remain within the protection of the two protein shells and the viral RNA-dependent RNA polymerase creates mRNA transcripts of the double-stranded viral genome. By remaining in the core, the viral RNA evades innate host immune responses called RNA interference that are triggered by the presence of double-stranded RNA.

During the infection, rotavirus produces mRNA for both protein biosynthesis and gene replication. Most of the rotavirus proteins accumulate in viroplasm, where the RNA is replicated and the DLPs are assembled. Viroplasm is formed around the cell nucleus as early as two hours after virus infection, and consists of viral factories thought to be made by two viral nonstructural proteins: NSP5 and NSP2. Inhibition of NSP5 by RNA interference results in a sharp decrease in rotavirus replication. The DLPs migrate to the endoplasmic reticulum where they obtain their third, outer layer (formed by VP7 and VP4). The progeny viruses are released from the cell by lysis.

History

One of Flewett's original electron micrographs

In 1943, Jacob Light and Horace Hodes proved that a filterable agent in the faeces of children with infectious diarrhoea also caused scours (livestock diarrhoea) in cattle. Three decades later, preserved samples of the agent were shown to be rotavirus. In the intervening years, a virus in mice was shown to be related to the virus causing scours. In 1973, Ruth Bishop and colleagues described related viruses found in children with gastroenteritis.

In 1974, Thomas Henry Flewett suggested the name rotavirus after observing that, when viewed through an electron microscope, a rotavirus particle looks like a wheel (rota in Latin); the name was officially recognised by the International Committee on Taxonomy of Viruses four years later. In 1976, related viruses were described in several other species of animals. These viruses, all causing acute gastroenteritis, were recognised as a collective pathogen affecting humans and animals worldwide. Rotavirus serotypes were first described in 1980, and in the following year, rotavirus from humans was first grown in cell cultures derived from monkey kidneys, by adding trypsin (an enzyme found in the duodenum of mammals and now known to be essential for rotavirus to replicate) to the culture medium. The ability to grow rotavirus in culture accelerated the pace of research, and by the mid-1980s the first candidate vaccines were being evaluated.

In 1998, a rotavirus vaccine was licensed for use in the United States. Clinical trials in the United States, Finland, and Venezuela had found it to be 80 to 100% effective at preventing severe diarrhoea caused by rotavirus A, and researchers had detected no statistically significant serious adverse effects. The manufacturer, however, withdrew it from the market in 1999, after it was discovered that the vaccine may have contributed to an increased risk for intussusception, a type of bowel obstruction, in one of every 12,000 vaccinated infants. The experience provoked intense debate about the relative risks and benefits of a rotavirus vaccine. In 2006, two new vaccines against rotavirus A infection were shown to be safe and effective in children, and in June 2009 the World Health Organization recommended that rotavirus vaccination be included in all national immunisation programmes to provide protection against this virus.

In 2015, India unveiled a cheaper vaccine with support of US National Institute of Health.

References

External links

Rotaviral Gastroenteritis
Classification and external resources
Specialty	Infectious disease
ICD-10	A08.0
ICD-9-CM	008.61
DiseasesDB	11667
MedlinePlus	000252
eMedicine	emerg/401
MeSH	D012400

• WHO Rotavirus web page
• Rotavirus on Centers for Disease Control and Prevention (CDC) site
• Viralzone: Rotavirus
• Vaccine Resource Library: Rotavirus
• DefeatDD.org
• Centers for Disease Control and Prevention (2012). "Ch. 18: Rotavirus". In Atkinson W, Wolfe S, Hamborsky J. Epidemiology and Prevention of Vaccine-Preventable Diseases (12th ed.). Washington DC: Public Health Foundation. pp. 263–274. 
• 3D macromolecular structures of Rotaviruses from the EM Data Bank(EMDB)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. ロタウイルス感染の臨床症状および診断 clinical manifestations and diagnosis of rotavirus infection
• 2. 小児に対するロタウイルスワクチン rotavirus vaccines for infants
• 3. 成人におけるウイルス性胃腸炎の疫学および病因 epidemiology and pathogenesis of viral gastroenteritis in adults
• 4. 新生児集中治療室における院内ウイルス感染症 nosocomial viral infections in the neonatal intensive care unit
• 5. 成人における急性ウイルス性胃腸炎のマネジメント management of acute viral gastroenteritis in adults

English Journal

• PolyAdenine cryogels for fast and effective RNA purification.

• Köse K1, Erol K2, Özgür E3, Uzun L4, Denizli A3.
• Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2016 Oct 1;146:678-86. doi: 10.1016/j.colsurfb.2016.07.003. Epub 2016 Jul 4.
• Cryogels are used effectively for many diverse applications in a variety of fields. The isolation or purification of RNA, one of the potential utilizations for cryogels, is crucial due to their vital roles such as encoding, decoding, transcription and translation, and gene expression. RNA principall
• PMID 27434154

• Epidemiology of rotavirus A diarrhea in Chókwè, Southern Mozambique, from February to September, 2011.

• Langa JS1,2, Thompson R1, Arnaldo P1, Resque HR2,3, Rose T2, Enosse SM1, Fialho A2, de Assis RM2, da Silva MF2,4, Leite JP2.
• Journal of medical virology.J Med Virol.2016 Oct;88(10):1751-8. doi: 10.1002/jmv.24531. Epub 2016 Mar 29.
• Acute diarrhea disease caused by Rotaviruses A (RVA) is still the leading cause of morbidity and mortality in children ≤5 years old in developing countries. An exploratory cross-sectional study was conducted between February and September, 2011 to determine the proportion of acute diarrhea caused
• PMID 27003797

• Norovirus diarrhea in Bangladesh, 2010-2014: prevalence, clinical features, and genotypes.

• Rahman M1, Rahman R1, Nahar S2, Hossain S1, Ahmed S1, Golam Faruque AS1, Azim T1.
• Journal of medical virology.J Med Virol.2016 Oct;88(10):1742-50. doi: 10.1002/jmv.24530. Epub 2016 Mar 29.
• Norovirus infections in diarrhea patients attending an urban and a rural hospital in Bangladesh were investigated. A total of 953 fecal specimens from both children and adults collected during 2010-2014 were tested for the presence of norovirus using real time PCR. One fourth (25%) of the specimens
• PMID 27003679

Japanese Journal

• Reassortant DS-1-like G1P[4] Rotavirus A strains generated from co-circulating strains in Vietnam, 2012/2013

• Microbiology and immunology 61(8), 328-336, 2017-08
• NAID 40021292939

• Changes in Rotavirus Genotypes before and after Vaccine Introduction : a Multicenter, Prospective Observational Study in Three Areas of Japan

• Japanese Journal of Infectious Diseases 70(4), 448-452, 2017-07
• NAID 40021275721

• Burden of Rotavirus and Enteric Bacterial Pathogens among Children under 5 Years of Age Hospitalized with Diarrhea in Suburban and Rural Areas in Kenya

• Japanese Journal of Infectious Diseases 70(4), 442-447, 2017-07
• NAID 40021275709

Related Pictures

---

★リンクテーブル★

リンク元	「LLCMK2細胞」「ロタウイルス」「rotaviral」
拡張検索	「rotavirus infection」「rotavirus vaccine」「rotavirus gastroenteritis」「rotavirus enteritis」

「LLCMK2細胞」

　　[★]

英

LLCMK2 cell

• サル腎上皮細胞

• 種：monkey, rhesus
• 組織：kidney

• ウイルス感受性：astrovirus、enterovirus、influenza A virus、influenza B virus、myxovirus、parainfluenza、parainfluenza、parainfluenza、poliovirus、poliovirus、poliovirus、poxvirus、rhinovirus、rotavirus

「ロタウイルス」

　　[★]

英

rotavirus

関

ウイルス

ウイルス学

• レオウイルス科ロタウイルス属

感染症

• 乳幼児下痢症、仮性コレラ

「rotaviral」

　　[★]

• adj.

• ロタウイルスの

関

rotavirus

「rotavirus infection」

　　[★]

ロタウイルス感染症、ロタウイルス感染

「rotavirus vaccine」

　　[★]

ロタウイルスワクチン

「rotavirus gastroenteritis」

　　[★]

ロタウイルス胃腸炎

「rotavirus enteritis」

　　[★] ロタウイルス性腸炎